TY - JOUR T1 - Peripheral Artery Disease and COVID-19 Outcomes: Insights from the Yale DOM-CovX Registry JF - medRxiv DO - 10.1101/2021.08.16.21262118 SP - 2021.08.16.21262118 AU - Kim G. Smolderen AU - Megan Lee AU - Tanima Arora AU - Michael Simonov AU - Carlos Mena-Hurtado Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/08/18/2021.08.16.21262118.abstract N2 - Background Both COVID-19 infection and peripheral arterial disease (PAD) cause hypercoagulability in patients, and it remains unknown whether PAD predisposes patients to experience worse outcomes when infected with SARS-CoV-2.Methods The Yale DOM-CovX Registry consecutively enrolled inpatients for SARS-CoV-2 between March 1, 2020, and November 10, 2020. Adjusted logistic regression models examined associations between PAD and mortality, stroke, myocardial infarction (MI), and major adverse cardiovascular events (MACE, all endpoints combined).Results Of the 3,830 patients were admitted with SARS-CoV-2, 50.5% were female, mean age was 63.1 ±18.4 years, 50.7% were minority race, and 18.3% (n = 693) had PAD. PAD was independently associated with increased mortality (OR=1.45, 95% CI 1.11-1.88) and MACE (OR=1.48, 95% CI 1.16-1.87). PAD was not independently associated with stroke (p=0.06) and MI (p=0.22).Conclusion Patients with PAD have a >40% odds of mortality and MACE when admitted with a SARS-CoV-2, independent of known risk factors.Competing Interest StatementDr. Smolderen reports grant support from Johnson & Johnson, Cardiva, Abbott, and she is a consultant for Optum Labs. Dr. Mena-Hurtado serves as a consultant for Abbott, Cook Medical, Medtronic, Cardinal Health, and Optum Labs LLC.Funding StatementNo external funding for this work was received.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was reviewed by the Yale Institutional Research Board and given the deidentified nature of the data, the research was deemed non-human subjects research.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is available upon request to the authors. ER -